TPST
Tempest Therapeutics·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 1
Bearish signal 1
Ample Liquidity
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About TPST
Tempest Therapeutics Inc
A clinical-stage biopharmaceutical company that develops molecular therapeutics to treat cancer by direct tumor-killing or activating tumor-specific immunity
Biological Technology
04/05/2011
04/30/2013
NASDAQ Stock Exchange
24
12-31
Common stock
2000 Sierra Point Parkway, Suite 400, Brisbane, California 94005
--
Tempest Therapeutics Inc was founded on April 5, 2011. The Company is a clinical-stage oncology company focused on developing and advancing novel oral therapies for the treatment of solid tumors using a deep scientific understanding of cancer biology and medicinal chemistry. The company is advancing clinical trials of two product candidates, TPST-1120 and TPST-1495, which are believed to be the first clinical-stage molecules designed to inhibit their respective targets; and two preclinical projects, one of which may be the first to target TREX-1, a key cellular enzyme that regulates the innate immune response of tumors.
Company Financials
EPS
TPST has released its 2025 Q2 earnings. EPS was reported at -2.07, versus the expected -2.65, beating expectations. The chart below visualizes how TPST has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
